We Can Detect Alzheimer’s Earlier. Will Medicare Pay For It?
New resources are making it possible to identify Alzheimer’s disease earlier than ever before. But a decades-old restriction on Medicare coverage has created an unexpected obstacle between scientific advancement and patient access.
By JEANNIE KIM
For decades, an Alzheimer’s diagnosis often came after memory loss and other cognitive symptoms had already become apparent. That is beginning to change. Advances in blood-based biomarkers, brain imaging, and other diagnostic technologies are allowing researchers and physicians to detect signs associated with Alzheimer’s disease much earlier.
But being able to detect a disease does not necessarily mean patients can access testing for it. Congress is currently considering the Alzheimer’s Screening and Prevention (ASAP) Act, bipartisan legislation that would create a pathway for Medicare to cover certain tools used for early Alzheimer’s detection. On September 16th, 2026, the bill advanced through the House Ways and Means Committee, bringing renewed attention to an unusual problem: federal law can influence not only how disease is treated, but when patients are able to find out they have it.
The Medicare Problem
Medicare provides health coverage to tens of millions of older Americans, the population most affected by Alzheimer’s disease. Yet federal law generally limits Medicare coverage of routine screening services unless Congress has specifically authorized them or another statutory coverage pathway applies.
This distinction between diagnosis and screening matters. Diagnostic testing typically investigates symptoms or a suspected condition. Screening attempts to identify disease before clear symptoms necessarily appear.
That system was created long before today’s Alzheimer’s detection technologies existed. As a result, scientific progress has produced an unusual gap: researchers are developing increasingly sophisticated ways to identify Alzheimer’s related changes earlier, while the federal insurance program that covers most Americans 65 and older operates under legal restrictions on preventive screening. The ASAP Act attempts to address that gap by establishing a Medicare coverage pathway for Alzheimer’s detection tools.
Why Earlier Detection Matters
Alzheimer’s disease develops over years, with biological changes potentially beginning long before severe cognitive symptoms appear. Earlier detection can give patients and families more time to consider treatment, partake in clinical trials, and make financial and legal decisions while patients retain greater independence.
The issue has become more significant as Alzheimer’s treatment itself changes. Newer therapies target biological features of the disease and may be most useful during earlier stages, increasing the importance of identifying eligible patients before substantial cognitive decline occurs.
Yet, expanding screening also raises questions. A test indicating an elevated risk or early biological signs of Alzheimer’s can carry enormous consequences for a patient even when the future course of the disease remains uncertain. Early detection therefore creates not only a medical decision, but a crucial legal and ethical one.
A Diagnosis Beyond the Doctor’s Office
An Alzheimer’s diagnosis can affect decisions extending far beyond medical treatment. Patients may begin considering estate planning, employment, long-term care, and who should eventually make decisions on their behalf. At the center of many of these issues is legal capacity: whether an individual can understand and make a particular decision. An Alzheimer’s diagnosis does not automatically mean someone lacks capacity. Cognitive decline varies substantially between individuals and across stages of disease.
Earlier detection can therefore give people more time to make important decisions themselves rather than waiting until their ability to communicate their preferences becomes uncertain. At the same time, earlier identification raises concerns about how information about cognitive decline could be used by others. As medicine becomes capable of detecting disease earlier, lawmakers will increasingly have to consider protections surrounding the information those tests produce.
When Scientific Progress Meets Federal Law
The debate surrounding the ASAP Act illustrates a larger challenge in healthcare law: scientific innovation can move faster than the legal systems responsible for paying for and regulating it. A Medicare rule written before modern Alzheimer’s biomarkers existed can ultimately determine whether millions of patients have access to those technologies. Changing medical capabilities therefore do not automatically change healthcare access. Sometimes, Congress has to change the law first.
The ASAP Act has received substantial bipartisan support, but its progression through Congress does not guarantee that it will become law. Questions will also remain about which detection tools Medicare should cover, how their effectiveness should be evaluated, and which patients should receive them.
What Questions Remain?
If Alzheimer’s can be detected before significant symptoms appear, how early should physicians look for it? Should every older American eventually be offered screening, or only those considered at higher risk? How should doctors explain a positive biomarker result when it cannot perfectly predict an individual patient’s future? And most importantly, what rights should someone have when medicine can identify cognitive decline before that decline meaningfully affects their everyday life?
The ASAP Act may appear to be a Medicare coverage bill, but underneath the question of who pays for an Alzheimer’s test lies a much larger issue.
Medicine is becoming increasingly capable of knowing about disease before patients become sick; the law must decide what happens once we know.
Sources & Further Reading
Alzheimer’s Association. “House Subcommittee Hearing Signals Growing Support for Early Alzheimer’s Detection.” Alzheimer’s Association, 2026.
Centers for Medicare & Medicaid Services. “Preventive and Screening Services.” CMS.gov, U.S. Department of Health and Human Services.
Congress.gov. Alzheimer’s Screening and Prevention Act. U.S. Congress, 2026.
National Institute on Aging. “Alzheimer’s Disease Fact Sheet.” National Institutes of Health, U.S. Department of Health and Human Services.
U.S. House Committee on Ways and Means. Alzheimer’s Screening and Prevention Act. U.S. House of Representatives, 2026.
Comments